1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Bellevue Group AG Buys Cigna Corp, Humana Inc, Evolent Health Inc, Sells Celgene Corp, Amgen Inc, Biogen Inc

Investment company Bellevue Group AG buys Cigna Corp, Humana Inc, Evolent Health Inc, Teladoc Health Inc, Bristol-Myers Squibb Company, Guardant Health Inc, Qiagen NV, Quidel Corp, WellCare Health Plans Inc, DexCom Inc, Abiomed Inc, Nektar Therapeutics Inc, Hutchison China Meditech, Integra Lifesciences Holdings Corp, Globus Medical Inc, Horizon Therapeutics PLC, Vocera Communications Inc, Oxford Immunotec Global PLC, LivaNova PLC, Inogen Inc, Intersect ENT Inc, Nevro Corp, Omnicell Inc, Zimmer Biomet Holdings Inc, Castlight Health Inc, BeiGene, Syneos Health Inc, iRhythm Technologies Inc, Molina Healthcare Inc, HMS Holdings Corp, Regeneron Pharmaceuticals Inc, Ascendis Pharma A/S, Amicus Therapeutics Inc, Neuronetics Inc, Veeva Systems Inc, uniQure NV, Inspire Medical Systems Inc, Tandem Diabetes Care Inc, HCA Healthcare Inc, Pfizer Inc, Quanterix Corp, bluebird bio Inc, Medidata Solutions Inc, Tabula Rasa HealthCare Inc, CVS Health Corp, Array BioPharma Inc, Radius Health Inc, Portola Pharmaceuticals Inc, GW Pharmaceuticals PLC, Exelixis Inc, Benefitfocus Inc, Amedisys Inc, argenx SE, Sage Therapeutics Inc, Zai Lab, Materialise NV, FibroGen Inc, Arena Pharmaceuticals Inc, The Medicines Co, Seattle Genetics Inc, Puma Biotechnology Inc, Ultragenyx Pharmaceutical Inc, Kura Oncology Inc, Regenxbio Inc, PTC Therapeutics Inc, Premier Inc, sells Celgene Corp, Amgen Inc, Biogen Inc, Ionis Pharmaceuticals Inc, Biomarin Pharmaceutical Inc, Macrogenics Inc, Horizon Therapeutics PLC, Ligand Pharmaceuticals Inc, Cerner Corp, Gilead Sciences Inc, Allergan PLC, Mylan NV, Neurocrine Biosciences Inc, Loxo Oncology Inc, Endo International PLC, Myriad Genetics Inc, Teva Pharmaceutical Industries, Ironwood Pharmaceuticals Inc, Cellectis SA, Adaptimmune Therapeutics PLC, Covetrus Inc, Intercept Pharmaceuticals Inc, Acceleron Pharma Inc, Intra-Cellular Therapies Inc, Healthcare Services Group Inc, Sarepta Therapeutics Inc, Mirati Therapeutics Inc, Voyager Therapeutics Inc, Intellia Therapeutics Inc, Iovance Biotherapeutics Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Bellevue Group AG. As of 2019Q1, Bellevue Group AG owns 134 stocks with a total value of $1.8 billion. These are the details of the buys and sells.

For the details of Bellevue Group AG's stock buys and sells, go to https://www.gurufocus.com/guru/bellevue+group+ag/current-portfolio/portfolio

These are the top 5 holdings of Bellevue Group AG
  1. Align Technology Inc (ALGN) - 334,679 shares, 5.28% of the total portfolio. Shares added by 7.68%
  2. Intuitive Surgical Inc (ISRG) - 150,999 shares, 4.78% of the total portfolio. Shares added by 8.79%
  3. Abbott Laboratories (ABT) - 1,040,587 shares, 4.61% of the total portfolio. Shares added by 6.57%
  4. Illumina Inc (ILMN) - 257,696 shares, 4.44% of the total portfolio. Shares added by 2.30%
  5. Teladoc Health Inc (TDOC) - 1,374,294 shares, 4.24% of the total portfolio. Shares added by 27.98%
New Purchase: Cigna Corp (CI)

Bellevue Group AG initiated holding in Cigna Corp. The purchase prices were between $159.69 and $199.81, with an estimated average price of $183.17. The stock is now traded at around $155.27. The impact to a portfolio due to this purchase was 1.48%. The holding were 165,657 shares as of .

New Purchase: Guardant Health Inc (GH)

Bellevue Group AG initiated holding in Guardant Health Inc. The purchase prices were between $34.3 and $97.98, with an estimated average price of $54.87. The stock is now traded at around $77.45. The impact to a portfolio due to this purchase was 0.47%. The holding were 109,652 shares as of .

New Purchase: Horizon Therapeutics PLC (HPR)

Bellevue Group AG initiated holding in Horizon Therapeutics PLC. The purchase prices were between $16.5 and $25.2, with an estimated average price of $20.53. The stock is now traded at around $23.60. The impact to a portfolio due to this purchase was 0.23%. The holding were 158,800 shares as of .

New Purchase: Syneos Health Inc (SYNH)

Bellevue Group AG initiated holding in Syneos Health Inc. The purchase prices were between $36.91 and $55.7, with an estimated average price of $48.45. The stock is now traded at around $43.42. The impact to a portfolio due to this purchase was 0.14%. The holding were 47,200 shares as of .

New Purchase: Ascendis Pharma A/S (ASND)

Bellevue Group AG initiated holding in Ascendis Pharma A/S. The purchase prices were between $62.15 and $129.99, with an estimated average price of $86.75. The stock is now traded at around $121.81. The impact to a portfolio due to this purchase was 0.12%. The holding were 18,200 shares as of .

New Purchase: Amicus Therapeutics Inc (FOLD)

Bellevue Group AG initiated holding in Amicus Therapeutics Inc. The purchase prices were between $9.58 and $13.92, with an estimated average price of $12.16. The stock is now traded at around $12.54. The impact to a portfolio due to this purchase was 0.11%. The holding were 150,000 shares as of .

Added: Humana Inc (HUM)

Bellevue Group AG added to a holding in Humana Inc by 93.84%. The purchase prices were between $262.61 and $310.3, with an estimated average price of $288.61. The stock is now traded at around $243.68. The impact to a portfolio due to this purchase was 1.09%. The holding were 152,477 shares as of .

Added: Evolent Health Inc (EVH)

Bellevue Group AG added to a holding in Evolent Health Inc by 3010.75%. The purchase prices were between $12.17 and $20.92, with an estimated average price of $15.96. The stock is now traded at around $14.22. The impact to a portfolio due to this purchase was 0.95%. The holding were 1,408,237 shares as of .

Added: Teladoc Health Inc (TDOC)

Bellevue Group AG added to a holding in Teladoc Health Inc by 27.98%. The purchase prices were between $46.23 and $69.99, with an estimated average price of $61.02. The stock is now traded at around $59.10. The impact to a portfolio due to this purchase was 0.93%. The holding were 1,374,294 shares as of .

Added: Bristol-Myers Squibb Company (BMY)

Bellevue Group AG added to a holding in Bristol-Myers Squibb Company by 42.93%. The purchase prices were between $45.12 and $53.8, with an estimated average price of $49.88. The stock is now traded at around $46.63. The impact to a portfolio due to this purchase was 0.55%. The holding were 695,824 shares as of .

Added: Qiagen NV (QGEN)

Bellevue Group AG added to a holding in Qiagen NV by 41.79%. The purchase prices were between $33.78 and $40.68, with an estimated average price of $37.87. The stock is now traded at around $37.25. The impact to a portfolio due to this purchase was 0.41%. The holding were 617,194 shares as of .

Added: WellCare Health Plans Inc (WCG)

Bellevue Group AG added to a holding in WellCare Health Plans Inc by 29.10%. The purchase prices were between $230.61 and $282.5, with an estimated average price of $258.4. The stock is now traded at around $272.85. The impact to a portfolio due to this purchase was 0.36%. The holding were 107,419 shares as of .

Sold Out: Biomarin Pharmaceutical Inc (BMRN)

Bellevue Group AG sold out a holding in Biomarin Pharmaceutical Inc. The sale prices were between $84.2 and $98.62, with an estimated average price of $92.66.

Sold Out: Ligand Pharmaceuticals Inc (LGND)

Bellevue Group AG sold out a holding in Ligand Pharmaceuticals Inc. The sale prices were between $105.93 and $142.47, with an estimated average price of $121.61.

Sold Out: Horizon Therapeutics PLC (HZNP)

Bellevue Group AG sold out a holding in Horizon Therapeutics PLC. The sale prices were between $19.49 and $29.01, with an estimated average price of $23.59.

Sold Out: Cerner Corp (CERN)

Bellevue Group AG sold out a holding in Cerner Corp. The sale prices were between $50.7 and $58.82, with an estimated average price of $55.63.

Sold Out: Allergan PLC (AGN)

Bellevue Group AG sold out a holding in Allergan PLC. The sale prices were between $132.09 and $160.79, with an estimated average price of $144.95.

Sold Out: Loxo Oncology Inc (LOXO)

Bellevue Group AG sold out a holding in Loxo Oncology Inc. The sale prices were between $131.02 and $234.75, with an estimated average price of $222.49.



Here is the complete portfolio of Bellevue Group AG. Also check out:

1. Bellevue Group AG's Undervalued Stocks
2. Bellevue Group AG's Top Growth Companies, and
3. Bellevue Group AG's High Yield stocks
4. Stocks that Bellevue Group AG keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK